

CFP SERVICES CHART

	British Columbia	Alberta	Saskatchewan
Care plans		\$100 per Comprehensive Annual Care Plan (CACP) (380,357 claims); \$60 per Standard Medication Management Assessment (SMMA) (55,843); \$20 per follow-up, max. 12 annually (1,778,993 for CACPs; 198,096 for SMMA); \$60 per SMMA for Diabetes and \$20 per follow-up, max. 4 annually (27,557 combined)	
Medication reviews / management	\$60 per Medication Review - Standard; \$70 per Medication Review - Pharmacist Consultation, max. 2 annually for both combined; \$15 per Medication Review Follow-Up, max. 4 annually (claims for all pending SEE NOTES)	Medication reviews a component of CACPs and SMMA (see Care plans above)	\$60 per Medication Assessment (seniors) (8,084 claims), max. 1 annually; \$20 per follow-up, max. 2 annually (2,175)
Pharmaceutical opinions			
Vaccination	\$12.10 for flu; \$18 for COVID-19 inc. \$5.90 to offset costs; \$11.41 for non-publicly funded vaccines as of Oct. 14, 2022 (claims for all pending SEE NOTES)	\$13 (971,241 claims for flu, 15,766 for pneumonia, 13,313 for Tdap); \$25 or \$35 (weekends/stat holidays) for COVID-19 (1,136,612); authority for other vaccinations, inc. travel vaccines. NOTE: Fee for COVID-19 reduced to \$17 as of Oct. 16, 2023 and to \$13 as of Apr. 1, 2024	\$14 for flu (168,610 claims); \$20 for COVID-19 (214,434); authority for other vaccinations, inc. travel vaccines
Administration of drugs by injection	\$11.41 as of Oct. 14, 2022 (exc. allergy serums and substances for cosmetic use; claims pending SEE NOTES)	\$20 (342,226 claims)	\$13 for medroxyprogesterone and, as of Jun. 13, 2022, Evusheld (5,790 claims combined)
Prescribing: renewals and adaptations	\$10 to renew or adapt, max. 2/drug every 6 months or one-time renewal for controlled substances (claims pending SEE NOTES)	\$20 to renew or adapt (inc. altering insulin orders and discontinuations) (1,308,878 claims for renewals; 180,598 for adaptations)	\$6 to renew, alter dosage form, max. 4/28 days, or alter missing information, max. 1/28 days; \$10 to continue prescription in emergency, max. 1/28 days (390,119 claims inc. reconciliations with prescribing [see "Prescribing authority: initial access"])
Prescribing: common or minor ailments	\$20 per assessment with or without prescribing for 21 conditions and contraception (inc. emergency contraception) as of Jun. 2023, as part of Pharmacare daily billing max. of \$78 (claims n/a SEE NOTES)	As part of CACPs and SMMA by those with additional prescribing authority (APA); outside of CACPs and SMMA, \$25 per assessment resulting in a prescription by those with APA (claims inc. under prescribing for initial access)	\$18 per assessment resulting in a prescription for 27 conditions (36,403 claims)
Prescribing: initial access or to manage ongoing therapy		\$25 per assessment for initiating prescription by those with APA (491,990 claims); \$20 per emergency prescription (31,208); \$20 per continuity of care prescription during declared "state of emergency" (1,633)	\$25 for medication reconciliations with prescribing (claims inc. under all Rx authority, see "Prescribing: adaptation"); authority to assess and prescribe in emergencies; authority to assess and prescribe for preventable diseases (e.g. HPV, varicella)
COVID-19 prevention and treatment	Selected pharmacies dispense govt-funded Paxlovid: \$30 for clinical assessment plus usual dispensing fee plus \$25 for follow-up (claims pending SEE NOTES)	<ul style="list-style-type: none"> \$10 plus dispensing fee to dispense govt-funded Paxlovid (12,758 claims) Pharmacists with APA can prescribe Paxlovid 	<ul style="list-style-type: none"> \$18 to assess, prescribe or make referral for Paxlovid plus \$20 to dispense (491 claims) \$20 to dispense Evusheld as of Jun. 13, 2022
Therapeutic substitution	\$17.20 (claims pending SEE NOTES)	\$20 (claims inc. under adaptations)	\$18 per substitution pending regulations
Trial prescriptions & refusals to fill	\$10 per trial (claims n/a); \$20 per refusal (claims n/a)	\$12.15 per trial plus \$20 for follow-up (claims n/a); \$20 per refusal (3,222)	\$11.85 per trial plus \$7.50 for follow-up (4 claims); 1.5X dispensing fee max. \$17.40 per refusal (15)
Deprescribing		\$20 (claims inc. under adaptations)	
Laboratory tests		Authority to order and interpret lab tests	Authority to order lab tests pending regulations
Point of care testing (POCT)	\$75 per case for distribution of COVID-19 rapid antigen tests	<ul style="list-style-type: none"> Authority for POCT within scope of practice \$60 per case for distribution of COVID-19 rapid antigen tests 	
Smoking cessation	\$30 (3 dispensing fees) per 12-week course of treatment	\$60 for SMMA for Tobacco Cessation; \$20 per follow-up, max. 4 annually (32,804 claims combined)	<ul style="list-style-type: none"> Up to \$300 annually (\$1 [individual] or \$2 [group] per minute) for Partnership to Assist with the Cessation of Tobacco (PACT) (3,428 claims) Authority to prescribe for smoking cessation as part of minor ailments
Opioid harm reduction	<ul style="list-style-type: none"> \$7.70 plus dispensing fee per witnessed dose of methadone (claims n/a) Govt-funded naloxone available through pharmacies 	\$12.15 for dispensing of govt-funded naloxone (59,352 claims)	<ul style="list-style-type: none"> \$3.50/day per witnessed dose for Methadone Managed Care (49,414 claims) and Suboxone Managed Care (13,459), max. 7 weekly \$16 for education for govt-funded naloxone available at selected pharmacies (1,666)
Other services	\$15 per Biosimilar Patient Support service during transition	\$20 per Assessment to Screen and/or Test for Infectious Disease, max. 5/day/pharmacy (not a POCT and currently for COVID-19 only; 1,320,602 claims) NOTE: Program ended Oct. 1, 2023	<ul style="list-style-type: none"> 1.5X dispensing fee max. \$17.40 for seamless care (368 claims) \$3.50/day for Direct Observed Therapy for Hepatitis C drugs (79) \$18 per Biosimilar Insulin Transition as of Feb. 27, 2023 (357 claims)

Manitoba **Ontario** **Quebec** **New Brunswick**

All content in **RED** indicates public funding limited to eligible beneficiaries of the provincial drug plan.
 NOTES: Information current as of October 20, 2023. Claims data are for fiscal year ending March 31, 2023. In **B.C., Ontario** and **Nova Scotia**, some or all claims data pending at time of publication or not available until the next fiscal year (for services begun after March 31, 2023). Check for updates at www.cfpnet.ca/publications. In **Manitoba**, claims for vaccinations may include non-publicly funded vaccines. In **Quebec**, private insurance plans pay the same professional service fees as the public plan, for most but not all of the services listed here. In all provinces, pharmacists have authority to prescribe emergency refills.

	\$60 for MedsCheck Annual, max. 1 annually (657,848 claims); \$75 for MedsCheck for Diabetes, max. 1 annually (187,750); \$150 for MedsCheck at Home, max. 1 annually (7,109); \$25 per follow-up (112,836 for MedsCheck; 83,883 for MedsCheck for Diabetes Education)		\$52.50 per PharmaCheck (low-income), max. 1 annually (11,499 claims)
	<ul style="list-style-type: none"> \$15 per Pharmaceutical Opinion \$15 per PO during Paxlovid dispensing (claims for all pending SEE NOTES) 	\$21.25 per Pharmaceutical Opinion (202,000 claims) NOTE: New PO on initiation of treatment to be implemented Apr. 1, 2024	
\$7 increased to \$13 as of Aug. 2, 2023 for flu (179,517 claims); \$20 for COVID-19 (300,701); \$7 for other publicly funded vaccines (3,224 for pneumonia; 1,015 for HPV; 5,932 for Tdap; 278 for Td)	\$8.50 for flu (2,190,841 claims); \$13 for COVID-19 (claims pending SEE NOTES); authority for other vaccinations inc. travel vaccines; authority pending for RSV vaccine	\$15.66 when administered by a pharmacist or \$12.91 by authorised staff, increased to \$16.44 and \$13.56 as of Apr. 2023 (648,000 claims for flu, 516,000 for COVID-19, 370,000 for other); \$16.44 or \$13.56 for shingles vaccine as of May 2023	\$13 (453,632 claims for flu, COVID-19 and pneumonia combined); authority for other vaccinations, inc. travel vaccines
Authority to administer drugs by injection	Authority to administer certain substances within specified limitations	\$20.31 increased to \$21.33 as of Apr. 2023 for demonstration purposes (1,500 claims) or in emergencies (claims n/a)	Authority to administer drugs by injection
Authority for continuity of care prescribing and prescription adaptations	Authority to renew and adapt	\$14.09 increased to \$14.79 as of Apr. 2023 per renewal (1,776,000 claims); \$22.31 increased to \$23.43 as of Apr. 2023 per adaptation (585,000)	\$20 to renew batch of 4 or more prescriptions, \$15 for 3 Rx, \$10 for 1 or 2 Rx, max. 4 annually (claims n/a); authority to adapt
\$20 per assessment for UTIs with or without prescribing (claims pending SEE NOTES); 13 conditions in total	\$19 (in-person) or \$15 (virtual) per assessment with or without prescribing for 13 conditions as of Jan. 2023 (135,137 claims); increased to 19 conditions as of Oct. 2023	\$22.31 increased to \$23.43 as of Apr. 2023 per assessment with or without prescribing for herpes zoster, influenza and COVID-19; \$18.04 increased to \$18.94 as of Apr. 2023 for other common conditions; 35 conditions in total (822,000 claims)	<ul style="list-style-type: none"> \$20 per assessment with or without prescribing for 9 conditions, max. 1-3 annually (claims n/a); \$20 per assessment or change in therapy for mild acne, max. 3 annually and \$12 for follow-up without change or discontinued; 33 conditions in total \$20 per assessment or change in therapy for Contraception Management, max. 3 annually; \$12 for follow-up without change or discontinued
Authority for prescribing by Extended Practice pharmacists within scope of their specialty; authority to prescribe in "state of emergency"	<ul style="list-style-type: none"> Authority to initiate Schedule 1 smoking cessation therapy; see Smoking cessation below for funding details Authority pending to prescribe oseltamivir 	<ul style="list-style-type: none"> \$17.47-\$20.85 increased to \$18.34-\$21.89 as of Apr. 2023 per initial evaluation to reach therapeutic target; \$18.94 per monthly follow-up for INR, \$23.67 per follow-up for other conditions, max. 2 annually (278,848 claims for INR; 96,000 for other conditions) \$19.34 to prescribe for emergency contraception (132,000) \$21.33 to prescribe and administer salbutamol and nonprescription drugs in an emergency (560) 	Authority to assess and prescribe in emergencies; for preventable diseases (e.g., HPV, varicella)
\$15 or usual dispensing fee if lower to dispense gov't-funded Paxlovid (claims pending SEE NOTES)	<ul style="list-style-type: none"> \$19 per assessment with or without prescribing Paxlovid; \$13.25 to dispense gov't-funded Paxlovid Up to \$31 to prepare and dispense remdesivir (claims for all pending SEE NOTES) 	<ul style="list-style-type: none"> \$22.31 increased to \$23.43 as of Apr. 2023 per assessment with or without prescribing Paxlovid as part of minor ailments (24,700 claims) \$10 plus usual dispensing fee to dispense first 30,000 Paxlovid prescriptions (\$5 after 30,000) 	\$20 per assessment with or without prescribing Paxlovid, or to adapt, complete or correct prescription, max. 3 annually
		\$18.04 increased to \$18.94 as of Apr. 2023 (111,000 claims)	Authority to substitute
	\$15 as part of Pharmaceutical Opinions (see above)	\$9.38 or \$10.03 per trial plus \$8.98 or \$9.62 for follow-up (2,400 claims); \$9.62 per refusal (30,000) NOTE: Separate billings discontinued for trials on Feb. 15, 2023 and for refusals on Mar. 31, 2023 as part of preparations for new PO on initiation of treatment to be implemented on Apr. 1, 2024	
		\$18.34 as of Feb. 15, 2023 (2,250 claims)	
Authority to order tests, receive and follow up with results		Authority to order and interpret lab tests	Authority to order and administer lab tests
	<ul style="list-style-type: none"> Authority to perform certain POCTs (glucose, HbA1C, lipids, PT/INR) for medication management \$42 for in-store COVID-19 PCR test; \$20 for screening if patient ineligible for PCRT (claims for all pending SEE NOTES) 	Authority to obtain throat specimen for medication management	<ul style="list-style-type: none"> Authority to perform, interpret and communicate results of POCT for medication management Authority to witness self-administration of COVID-19 rapid antigen test and certify result
\$100 to assess and prescribe (881 claims); \$20 per follow-up, max. 9 annually (1,398) NOTE: Funded under a social impact bond	\$40 for initial consult; \$15 per primary follow-up, max. 3; \$10 per secondary follow-up, max. 4; max. \$125 annually (claims pending SEE NOTES)	\$18.04 increased to \$18.94 as of Apr. 2023 to prescribe for smoking cessation (claims inc. under minor ailments)	Authority to prescribe for smoking cessation as part of minor ailments
Gov't-funded naloxone available through participating pharmacies	<ul style="list-style-type: none"> \$10 for dispensing injectable or intranasal gov't-funded naloxone; \$25 for training for initial injectable naloxone (claims n/a) Dispensing fee for each of: daily dose of methadone; daily dose of witnessed buprenorphine/naloxone; all carry doses dispensed at one time; any combination of witnessed and carry doses dispensed at one time 	\$20.31 increased to \$21.33 as of Apr. 2023 for training for gov't-funded naloxone (11,769 claims)	
	<ul style="list-style-type: none"> \$42 for specimen collection for lab COVID-19 PCR test; \$15 for handling self-collected specimen for PCRT, increased to \$35 when pharmacist is ordering clinician Authority to perform procedure on tissue below dermis with lancet-type device to demonstrate proper use Authority to administer certain substances by inhalation \$15 per Biosimilars Patient Support service during switch period (Mar. 31 to Dec. 28, 2023) 	\$9.96 increased to \$10.18 as of Apr. 2023 per transmission of medication profile (170,472 claims); \$27.74 increased to \$29.13 per hospital discharge support (69,000); \$44.63 increased to \$46.86 per prescriber-requested consult (24,700); \$33.30 increased to \$34.97 per palliative care support (10,000); \$19.65 increased to \$21.66 per consult for medical abortion (512); \$31.98 increased to \$36.68 per on-call service (claims n/a)	

CFP SERVICES CHART

Services, fees and claims data for government-sponsored pharmacy programs as of October 20, 2023

	Nova Scotia	Prince Edward Island	Newfoundland and Labrador
Care plans			
Medication reviews / management	\$52.50 per Basic Medication Review (4,727 claims); \$150 per Advanced Medication Review for seniors (claims pending SEE NOTES); \$20 per follow-up, max. 2 annually (509)	\$52.50 per Basic Medication Review (2,995 claims); \$65 per Diabetes Medication Review (1,392); \$20 per follow-up for Basic Medication Review, max. 4 annually (1,970); \$25 per follow-up for Diabetes Medication Review, max. 4 annually (875)	\$52.50 per Medication Review, max. 72/ pharmacy annually (2,222 claims)
Pharmaceutical opinions			
Vaccination	• \$12.85 for flu up from \$12.55 as of Apr. 2023 (235,279 claims); \$18 for COVID-19 (394,536); \$18 for meningococcal B as of May 2023	\$13 for flu (37,041 claims); \$20 for COVID-19 (47,901); \$20 for Shingrix (19,663); authority for other vaccinations, inc. travel vaccines	\$13 for flu (87,256 claims); \$17 for COVID-19 (82,282); authority for other vaccinations, inc. travel vaccines
Administration of drugs by injection	Authority to administer drugs by injection	Authority to administer drugs by injection	Authority to administer drugs by injection
Prescribing: renewals and adaptations	\$20 to renew batch of 4 or more prescriptions (15,155 claims), \$12 for up to 3 Rx (196,134); \$14 per Prescription Adaptation (2,032) NOTE: Funding for adaptations expanded to all residents as of Jul. 2023	\$20 per renewal as of Oct. 18, 2022, max. 4 annually (16,801 claims); 1.3 times dispensing fee up to \$16.50 per adaptation (363)	<ul style="list-style-type: none"> • \$11.96 or \$12 per renewal (77,187 claims) NOTE: Funding expanded to all residents as of Apr. 2023 with following fee structure: \$20 to renew batch of 4 or more prescriptions, \$15 for 3 Rx, \$10 for 1 or 2 Rx, max. 4 annually • \$11.96 or \$12 per Medication Management adaptation (4,421 claims)
Prescribing: common or minor ailments	<ul style="list-style-type: none"> • \$20 per assessment with or without prescribing for herpes zoster (1,705 claims), Lyme disease (claims n/a) and UTIs (19,887), max. 2 annually; 35 conditions in total • \$20 per annual assessment with or without prescribing for Contraception Management (3,314); \$20 per follow-up with change, max. 1 annually; \$12 per follow-up with no change, max. 1 annually (1,857) 	\$25 per assessment with or without prescribing as of Oct. 18, 2022 (7,645 claims for UTIs); 35 conditions in total	<ul style="list-style-type: none"> • \$20 per assessment with or without prescribing for 9 conditions as of Apr. 4, 2023, max. 2-4 annually; 33 conditions in total • \$20 per assessment with or without prescribing for hormonal contraception as of Apr. 4, 2023, max. 3 annually; \$20 per follow-up with or without change, max. 3 annually; \$20 per follow-up with discontinuation and/ or referral, max. 3 annually
Prescribing: initial access or to manage ongoing therapy	Authority to assess and prescribe in emergencies; for preventable diseases (e.g., HPV, varicella); for diagnosis provided by primary care provider	Authority to assess and prescribe in emergencies	Authority to assess and prescribe for 19 preventable diseases (eg, HPV, varicella)
COVID-19 prevention and treatment	<ul style="list-style-type: none"> • \$20 per assessment with or without prescribing budesonide (2,654 claims) • Selected pharmacies dispense Paxlovid; \$3.50 plus dispensing fee (3,061) 	<ul style="list-style-type: none"> • \$25 per assessment with or without prescribing Paxlovid as part of common ailments (870 claims) • \$5 plus dispensing fee to dispense Paxlovid (7,682) 	<ul style="list-style-type: none"> • \$20 to assess eligibility for Paxlovid (5,306 claims); \$11.96 to dispense (4,591) • \$7.50 to provide rapid antigen test (1,636)
Therapeutic substitution	\$26.25 (420 claims) NOTE: Funding expanded to all residents as of Jul. 2023	1.3X dispensing fee max. \$16.50 (11 claims)	\$11.96 or \$12 (claims n/a)
Trial prescriptions & refusals to fill	\$14 per refusal (26 claims)	1.3X dispensing fee max. \$16.50 per refusal (23 claims)	\$23.92 or \$24 per refusal (5 claims)
Deprescribing	Authority to taper doses as part of adaptations		\$23 per assessment for SaferMedsNL (939 claims for PPIs, 634 for sedatives); \$10 per follow-up (185 for PPIs, 85 for sedatives)
Laboratory tests	Authority to order lab tests within Community Pharmacy Primary Care Clinic pilot	Authority to order lab tests pending health system operationalization	
Point of care testing (POCT)	<ul style="list-style-type: none"> • Authority to perform POCT for medication management • \$50 per month for Community Pharmacist-led Anticoagulation Management Service inc. INR test (18,160 claims) • Authority to administer COVID-19 rapid antigen test and certify result for travel 	Authority to perform glucose, HbA1C and INR tests pending regulations	
Smoking cessation	Authority to prescribe for smoking cessation as part of minor ailments	Authority to prescribe for smoking cessation as part of common ailments	\$20 per assessment with or without prescribing for quit-smoking therapies as of Apr. 4, 2023, as part of program for common conditions
Opioid harm reduction	\$25 for dispensing and education for provincially funded naloxone (claims n/a)		\$3 per carry for opioid agonist therapy (OAT, claims n/a); \$50 per delivery of OAT for those isolating due to COVID-19 (97 claims)
Other services			<ul style="list-style-type: none"> • \$50 per assessment and dispensing for medical abortion (373 claims) • Authority to administer drugs by inhalation

Sources: Provincial pharmacy associations, provincial ministries of health

Made possible with financial support from



Prepared by Canadian Foundation for Pharmacy www.cfpnet.ca